IL1B, Canakinumab Biosimilar

Size

£604.00

SKU:: 591735
Purity:: Purified by Protein A/G affinity chromatography. Endotoxin: ≤1EU/mg (LAL)
Storage Conditions:: -20°C
Supplier:: United States Biological
Host:: Human
Immunogen:: Recombinant protein corresponding to human IL1B, expressed in CHO cells.
Format:: Supplied as a liquid in PBS. No preservative added.
Extra Details:: Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. Applications: Suitable for use in Functional Assays. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.